Amberstone Biosciences

Amberstone Biosciences, Inc. is an early-stage biotechnology company focused on developing next-generation T cell engagers (TCEs) for the treatment of solid tumors. The company's proprietary T-MATE platform leverages the acidic environment found in tumor microenvironment to locally activate TCEs, thereby minimizing on-target toxicity and enabling the development of safer and more effective therapeutics. Amberstone is advancing a diverse pipeline of T-MATE-based therapeutics for solid tumors that are intractable with conventional TCEs. The company is headquartered in Irvine, California.